VISTN Vistin Pharma ASA

Disclosure of voting rights at AGM in Vistin Pharma ASA

Disclosure of voting rights at AGM in Vistin Pharma ASA

Oslo, Norway, 22 May 2025

In relation to the Annual General Meeting in Vistin Pharma ASA (OSE: VISTN), on the 22th of May, the Company's Chair of the Board, Øyvin Brøymer, has received open proxies to represent a total of 5 156 012 shares in the Company at the AGM, corresponding to 11.63% of the total number of votes and shares in the Company. Together with the 14 509 280 shares held by Øyvin Brøymer through Intertrade Shipping AS, he will represent a total of 19 665 292 votes at the AGM, corresponding to a total of 44,35% of the total number of shares and votes in the Company. The proxies are only valid for the AGM and will lapse thereafter.



EN
22/05/2025

Underlying

VISTNVistin Pharma ASA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Vistin Pharma ASA

 PRESS RELEASE
Free
VISTN Vistin Pharma A...

Vistin Pharma ASA: Third quarter and YTD 2025 financial results

Vistin Pharma ASA: Third quarter and YTD 2025 financial results Vistin Pharma ASA: Third quarter and YTD 2025 financial results Oslo, Norway, 31st of October 2025 Vistin Pharma ASA (VISTN) today announces the financial results for the third quarter of 2025. Revenue in the third quarter ended at MNOK 109 compared to MNOK 106 in Q3 2024. The increase in revenue was driven by 10% higher sales volume. Revenue YTD 2025 ended at MNOK 342 compared to MNOK 316 YTD last year, an increase of 8% Third quarter EBITDA ended at MNOK 28 compared to MNOK 29 in Q3 2024. EBITDA of MNOK 28 positively affe...

16h / 56m 1 EN
 PRESS RELEASE
Free
VISTN Vistin Pharma A...

Vistin Pharma ASA: Invitation to Q3 2025 conference call

Vistin Pharma ASA: Invitation to Q3 2025 conference call Oslo, Norway, 24 October 2025 Vistin Pharma ASA (VISTN) will release its third quarter and YTD 2025 results on Friday 31st of October 2025. Vistin Pharma will host a conference call for all shareholders and interested parties on the same day at 08:30 CET. There will be a Q&A session following the management discussion. The conference call will be held in English. The third quarter conference call will be available via web and audio through the following access points: Webcast: Telephone conference (online registration): ***** ...

October 24, 2025 1 EN
 PRESS RELEASE
Free
VISTN Vistin Pharma A...

Vistin Pharma ASA: Second quarter and YTD 2025 financial results

Vistin Pharma ASA: Second quarter and YTD 2025 financial results Oslo, Norway, 15th of August 2025 Vistin Pharma ASA (VISTN) today announces the financial results for the second quarter of 2025. Revenue in the second quarter ended at MNOK 118 compared to MNOK 106 in Q2 2024. The increase in revenue was driven by 17% higher sales volume. Revenue for first half of 2025 ended at MNOK 233 compared to MNOK 210 YTD last year, an increase of 11%. Second quarter EBITDA ended at MNOK 30 compared to MNOK 27 in Q2 2024, representing 11% increase. EBITDA was positively affected by increased sales...

August 15, 2025 1 EN
 PRESS RELEASE
Free
VISTN Vistin Pharma A...

Vistin Pharma ASA: Invitation to Q2 2025 conference call

Vistin Pharma ASA: Invitation to Q2 2025 conference call Oslo, Norway, 08 August 2025 Vistin Pharma ASA will release its second quarter and YTD 2025 results on Friday 15th of August 2025. Vistin Pharma will host a conference call for all shareholders and interested parties at the same day at 08:30 CET. There will be a Q&A session following the management discussion. The conference call will be held in English. The second quarter conference call will be available via web and audio through the following access points: Webcast: Telephone conference (online registration): ***** For fur...

August 8, 2025 1 EN
 PRESS RELEASE
Free
VISTN Vistin Pharma A...

Ex dividend NOK 1.25 today

Ex dividend NOK 1.25 today The shares in Vistin Pharma ASA (VISTN) will be traded ex dividend NOK 1.25 as from today, 04.06.2025.

June 4, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch